Sanders Director, Tri-Institutional Therapeutics Discovery Institute, Inc
Dr. Peter T. Meinke is Sanders Director & CEO at the Sanders Tri-Institutional Therapeutics Discovery Institute (TDI) and also is Assistant Professor, Pharmacology, at Weill Cornell Medicine. TDI is a unique alliance that connects researchers from Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine with collaborators from across the globe to remove the barriers that impede drug discovery in academic settings.
Peter has extensive experience in all stages of drug discovery from target validation through early clinical development, resulting in 13 development compounds that advanced into the clinic in seven distinct therapeutic areas. Programs under his direct supervision produced one drug: NS5A inhibitor elbasvir for hepatitis C for which he was recognized with the ACS Heroes of Chemistry award in 2017. Elbasvir is combined with grazoprevir (trade name Zepatier) to completely clear Hepatitis C infection.